Anavex develops innovative oral medicines aimed at neurodegenerative and neurodevelopmental diseases, with a focus on advancing brain health for patients.
NASDAQ: AVXL
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.
Access Anavex presentations outlining our strategy, clinical progress, and long-term vision, providing investors and stakeholders with clear insights into our programs and milestones.
View Anavex’s upcoming participation in scientific, medical, and investor events, including conferences, presentations, and public webcasts.
Meet Anavex’s executive leadership and scientific advisors, whose experience in drug development, clinical research, and regulatory science guides the Company’s strategic direction.
Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the...
Prof. Dr. Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute....
Juan Carlos Lopez-Talavera, MD, PhD, brings over 20 years of leadership experience in managing registrational clinical trials and advancing patient...
Prof. Dr. Grimmer is a board-certified psychiatrist and psychotherapist and an Associate Professor working as a Specialist Registrar at the...
Steffen Thomas, PhD, has over 15 years of experience as a European patent attorney and is currently practicing at Epping...
Wolfgang Liedtke, MD, PhD, Senior Vice President, Global Head of Neurology, is a board-certified neurologist who brings more than 25...
Explore company announcements covering major milestones, clinical trial results, regulatory developments, and strategic initiatives across our programs.
Anavex Life Sciences is covered by the analysts listed below. Analyst opinions, estimates, or forecasts are their own and do not represent the views of Anavex Life Sciences or its management.
| Analyst | Firm |
|---|---|
| Raghuram Selvaraju PhD
Managing Director of Equity Research | H.C. Wainwright |
| Soumit Roy, PhD
Managing Director of Healthcare Research | Jones Trading |
| Jason Kolbert
Managing Director | EF Hutton |
Anavex is committed to strong corporate governance practices grounded in transparency, ethical conduct, and responsible decision-making to support long-term value creation.
Materials on this website may contain information about the future plans and prospects of Anavex Life Sciences Corp. and its representatives that constitute forward-looking statements for the purposes of the safe harbor provisions under the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ materially from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any “phase” of clinical trials. We also cannot be sure of the clinical outcome with regards to efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.
In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, Anavex Life Sciences Corp. will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date.
| Industry | Biopharmaceutical |
|---|---|
| Sector | New Drug Discovery |
| Fiscal Year-End | September 30 |
| Shares Issued and Outstanding | 82,112,511* |
| Stock Purchase Warrants | 160,000 ** |
| Stock Options | 14,109,363** |
| Fully Diluted | 96,355,874** |
| Cash | $143.8 million |
| Debt | Nil ** |
| Financial Statements & Filings | Anavex's filings can be found on EDGAR |
| Investor Relations | 1-844-689-3939
ir@anavex.com |
| Ticker | Industry | Sector | Fiscal Year-End | Shares Issued and Outstanding |
|---|---|---|---|---|
| NASDAQ: AVXL | Biopharmaceutical | New Drug Discovery | September 30 | 89,348,107* |
| Stock Purchase Warrants | Stock Options | Fully Diluted | Cash |
|---|---|---|---|
| 160,000 ** | 14,961,583** | 101,790,104** | $102.6 million** |
| Debt | Financial Statements & Filings | Investor Relations |
|---|---|---|
| Nil ** | Anavex's filings can be found on EDGAR | 1-844-689-3939
ir@anavex.com |
* As of November 25, 2025
** As of September 30, 2025